title: Emerging oral therapies for multiple sclerosis.
abstract: Despite notable advances in the understanding of multiple sclerosis (MS) and the availability of several treatment options, there is a need for therapies that are more effective, safe, convenient, and well tolerated. Several new oral MS therapies are being investigated. Because data on these new therapies continue to emerge, nurses will play a pivotal role in educating patients regarding the benefits and risks of potential treatments and in monitoring patients for response, safety, tolerability, and adherence. This article reviews the oral MS therapies recently approved as well as those currently in development or submitted for Food and Drug Administration approval.
authors.affiliation: William C. Baird Multiple Sclerosis Research Center, Jacobs Neurological Institute, University at Buffalo, The State University of New York, Buffalo, NY, USA. cmiller@TheJNI.org
authors.forename: Colleen E
authors.initials: CE
authors.lastname: Miller
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Umhauer
mesh_terms: D000284:Administration, Oral; D016903:Drug Monitoring; D004509:Education, Nursing, Continuing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing*; D012307:Risk Factors
chemical_list: D007166:Immunosuppressive Agents